Lymphatica Medtech, a clinical-stage company based in Lausanne, Switzerland, specialising in innovative treatments for lymphoedema, has raised EUR 17.9 million in a Series B financing. This investment will accelerate the clinical development and validation of LymphoDrain, a revolutionary implantable device designed to treat lymphoedema, a chronic vascular condition that currently has no cure and affects millions of people worldwide. The first of its kind, LymphoDrain is easy to implant subcutaneously using a minimally invasive technique and is designed to offer unprecedented benefits to patients by locally and actively replacing the drainage function of lymphatic vessels.
The financing round was co-led by Panakes Partners, TechWald Holding and the Digital Transition Fund of CDP Venture Capital, with the participation of Occident, Zürcher Kantonalbank and business angels from the Investors Club via Simon Fiduciaria. Existing investors, including High-Tech Gründerfonds (HTGF), also participated in this round.
To support its growth, Lymphatica has also opened a subsidiary in Italy, which will be responsible for expanding research and development, production and clinical operations.
Lymphatica is further strengthened with the appointment of Dan Rose as the new Chairman of the Board; Rose brings with him significant leadership experience from companies LimFlow (acquired by Inari Medical), Direct Flow Medical, Sequana Medical and Medtronic. In addition, Alessio Beverina, managing partner of Panakes, and Lukas Guenther, chief investment officer of TechWald Next, have joined the board alongside current independent board member Nanci Govinder.
“We are extremely pleased to have successfully concluded our Series B financing round, which will allow us to further advance the clinical development of our cutting-edge technology for lymphoedema patients,” Marco Pisano, CEO and co-founder of Lymphatica Medtech, said in a note. “With the support of our new and current investors and the addition of highly experienced figures to our board of directors, we are getting closer to our goal of offering an innovative and transformative solution that will significantly improve the quality of life of people suffering from this chronic condition.
Valentina Triacca, COO and co-founder of Lymphatica Medtech, adds: “Millions of people live with chronic lymphoedema and current treatment options do not offer adequate solutions. This investment allows us to continue developing LymphoDrain, our innovative device that has already shown promising results in a pilot feasibility study”.
Dan Rose says: “Lymphatica has made impressive progress in developing a compelling technology with the potential to transform care and improve the lives of the many lymphoedema patients. It is a privilege to join the Board as Chairman and support the efforts of this great team”.
Alessio Beverina, managing partner of Panakes: “Lymphatica is addressing a huge unmet medical need, with over 10 million people suffering from lymphoedema. This technology has the potential to transform the lives of those patients.”
Lukas Guenther, CIO of TechWald, emphasises how “with its technology, Lymphatica is well positioned to bring true sustainable clinical innovation to the treatment of lymphoedema, with great benefit for patients, clinicians and healthcare systems in various countries around the world.”
ALL RIGHTS RESERVED ©